|
AIDS |
acquired immunodeficiency syndrome |
|
BATTLE |
Biomarker-based Approaches of Targeted Therapy for Lung Cancer Elimination |
|
BRAF |
Rapidly Accelerated Fibrosarcoma (B family) |
|
CaBIG |
cancer Biomedical Informatics Grid |
|
CDER |
Center for Drug Evaluation and Research |
|
CDRH |
Center for Devices and Radiological Health |
|
CEO |
chief executive officer |
|
CGL |
chronic granulocytic leukemia |
|
CITN |
Cancer Immunotherapy Trials Network |
|
CMS |
Center for Medicare & Medicaid Services |
|
CRADA |
Cooperative Research and Development Agreement |
|
CTEP |
Cancer Therapy Evaluation Program |
|
CTLA-4 |
Cytotoxic T-Lymphocyte Antigen 4 |
|
DCE-MRI |
dynamic contrast enhanced-magnetic resonance imaging |
|
DOJ |
Department of Justice |
|
EGFR |
epidermal growth factor receptor |
|
EMA |
European Medicines Agency |
|
ER |
estrogen-receptor |
|
FDA |
Food and Drug Administration |
|
FNIH |
Foundation for the National Institutes of Health |
|
FTC |
Federal Trade Commission |
|
GSK |
GlaxoSmithKline |
|
HER2 |
human epidermal growth factor receptor 2 |
|
HIV |
Human Immunodeficiency Virus |
|
HPV |
human papillomavirus |
|
IGF |
insulin-like growth factor |
|
IIP |
instantaneous inhibitory potential |
|
IND |
Investigational New Drug |
|
IP |
intellectual property |
|
IRB |
Institutional Review Board |
|
I-SPY TRIAL |
Investigation of Serial studies to Predict Your Therapeutic Response with Imaging And moLecular analysis |
|
LCMV |
lymphocytic choriomeningitis virus |
|
MAPK |
mitogen-activated protein kinase |
|
MEK |
mitogen-activated protein kinase kinase |
|
MET |
Methylnitronitrosoguanidine-HOS (Human osteosarcoma) Transforming gene |
|
MTA |
Material Transfer Agreement |
|
mTORC1 |
mammalian target of rapamycin complex-1 |
|
NCDDG |
National Cooperative Drug Discovery Groups |
|
NCI |
National Cancer Institute |
|
NERF |
non-exclusive royalty-free |
|
NIAID |
National Institute of Allergy and Infectious Diseases |
|
NIH |
National Institutes of Health |
|
NOD |
non-obese diabetic |
|
OS |
overall survival |
|
PathCR |
pathological complete response |
|
PET |
positron emission tomography |
|
PFS |
progression-free survival |
|
PI3K |
phosphatidylinositol 3-kinase |
|
PPTP |
Pediatric Preclinical Testing Program |
|
R&D |
research and development |
|
SOC |
standard of care |
|
START |
Standard Terms of Agreement for Research Trial |
|
VEGF |
vascular endothelial growth factor |
